SG177225A1 - Cancer-related protein kinases - Google Patents
Cancer-related protein kinases Download PDFInfo
- Publication number
- SG177225A1 SG177225A1 SG2011095569A SG2011095569A SG177225A1 SG 177225 A1 SG177225 A1 SG 177225A1 SG 2011095569 A SG2011095569 A SG 2011095569A SG 2011095569 A SG2011095569 A SG 2011095569A SG 177225 A1 SG177225 A1 SG 177225A1
- Authority
- SG
- Singapore
- Prior art keywords
- epha2
- lmtk2
- arg
- tyk2
- ack1
- Prior art date
Links
- 108060006633 protein kinase Proteins 0.000 title claims abstract description 44
- 102000001253 Protein Kinase Human genes 0.000 title claims abstract description 43
- 206010028980 Neoplasm Diseases 0.000 title claims description 49
- 201000011510 cancer Diseases 0.000 title claims description 38
- 101001038335 Homo sapiens Serine/threonine-protein kinase LMTK2 Proteins 0.000 claims abstract description 130
- 102100040292 Serine/threonine-protein kinase LMTK2 Human genes 0.000 claims abstract description 130
- 102100036409 Activated CDC42 kinase 1 Human genes 0.000 claims abstract description 95
- 101000928956 Homo sapiens Activated CDC42 kinase 1 Proteins 0.000 claims abstract description 95
- 229920001184 polypeptide Polymers 0.000 claims abstract description 93
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 93
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 93
- 101150097734 EPHB2 gene Proteins 0.000 claims abstract description 86
- 102100031968 Ephrin type-B receptor 2 Human genes 0.000 claims abstract description 86
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims abstract description 85
- 101000878540 Homo sapiens Protein-tyrosine kinase 2-beta Proteins 0.000 claims abstract description 85
- 108091000080 Phosphotransferase Proteins 0.000 claims abstract description 85
- 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 claims abstract description 85
- 102000020233 phosphotransferase Human genes 0.000 claims abstract description 84
- 101150076616 EPHA2 gene Proteins 0.000 claims abstract description 81
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims abstract description 81
- 102100040293 Serine/threonine-protein kinase LMTK1 Human genes 0.000 claims abstract description 76
- 101710118516 Serine/threonine-protein kinase LMTK1 Proteins 0.000 claims abstract description 76
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims abstract description 70
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims abstract description 70
- VNEOHNUYPRAJMX-UHFFFAOYSA-N 3-[[2-[[2-amino-3-(1h-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-4-[[1-(butoxycarbonylamino)-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid Chemical compound C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(CC(C)C)C(=O)NC(CC(O)=O)C(=O)NC(C(=O)NC(=O)OCCCC)CC1=CC=CC=C1 VNEOHNUYPRAJMX-UHFFFAOYSA-N 0.000 claims abstract description 69
- 101000606465 Homo sapiens Inactive tyrosine-protein kinase 7 Proteins 0.000 claims abstract description 69
- 102100039813 Inactive tyrosine-protein kinase 7 Human genes 0.000 claims abstract description 69
- -1 CSFR1 Proteins 0.000 claims abstract description 66
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 claims abstract description 66
- 102100029166 NT-3 growth factor receptor Human genes 0.000 claims abstract description 66
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 claims abstract description 66
- 108010064892 trkC Receptor Proteins 0.000 claims abstract description 66
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims abstract description 63
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims abstract description 63
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 claims abstract description 61
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 claims abstract description 61
- 108010055323 EphB4 Receptor Proteins 0.000 claims abstract description 59
- 102100031983 Ephrin type-B receptor 4 Human genes 0.000 claims abstract description 59
- 101001026790 Homo sapiens Tyrosine-protein kinase Fes/Fps Proteins 0.000 claims abstract description 58
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims abstract description 58
- 102100037333 Tyrosine-protein kinase Fes/Fps Human genes 0.000 claims abstract description 58
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims abstract description 58
- 238000000034 method Methods 0.000 claims abstract description 58
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims abstract description 57
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims abstract description 57
- 101150016325 EPHA3 gene Proteins 0.000 claims abstract description 53
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 claims abstract description 53
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 claims abstract description 52
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 claims abstract description 51
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 claims abstract description 49
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims abstract description 49
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims abstract description 48
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims abstract description 48
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims abstract description 47
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 claims abstract description 45
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 claims abstract description 45
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims abstract description 43
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims abstract description 43
- 101001103033 Homo sapiens Tyrosine-protein kinase transmembrane receptor ROR2 Proteins 0.000 claims abstract description 42
- 102100039616 Tyrosine-protein kinase transmembrane receptor ROR2 Human genes 0.000 claims abstract description 42
- 102100035080 BDNF/NT-3 growth factors receptor Human genes 0.000 claims abstract description 41
- 102100031982 Ephrin type-B receptor 3 Human genes 0.000 claims abstract description 41
- 101000596896 Homo sapiens BDNF/NT-3 growth factors receptor Proteins 0.000 claims abstract description 41
- 101001064458 Homo sapiens Ephrin type-B receptor 3 Proteins 0.000 claims abstract description 41
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims abstract description 41
- 101000892986 Homo sapiens Tyrosine-protein kinase FRK Proteins 0.000 claims abstract description 41
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims abstract description 41
- 102100040959 Tyrosine-protein kinase FRK Human genes 0.000 claims abstract description 41
- 102100027907 Cytoplasmic tyrosine-protein kinase BMX Human genes 0.000 claims abstract description 37
- 101150078651 Epha4 gene Proteins 0.000 claims abstract description 37
- 102100021616 Ephrin type-A receptor 4 Human genes 0.000 claims abstract description 37
- 101000935548 Homo sapiens Cytoplasmic tyrosine-protein kinase BMX Proteins 0.000 claims abstract description 37
- 102100040177 Tyrosine-protein kinase Tec Human genes 0.000 claims abstract description 37
- 101001047681 Homo sapiens Tyrosine-protein kinase Lck Proteins 0.000 claims abstract description 34
- 102100024036 Tyrosine-protein kinase Lck Human genes 0.000 claims abstract description 34
- 102100036725 Epithelial discoidin domain-containing receptor 1 Human genes 0.000 claims abstract description 33
- 101710131668 Epithelial discoidin domain-containing receptor 1 Proteins 0.000 claims abstract description 33
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 claims abstract description 33
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 claims abstract description 33
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims abstract description 32
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims abstract description 32
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims abstract description 30
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 claims abstract description 30
- 102100031167 Tyrosine-protein kinase CSK Human genes 0.000 claims abstract description 30
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 claims abstract description 28
- 101001022129 Homo sapiens Tyrosine-protein kinase Fyn Proteins 0.000 claims abstract description 26
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 claims abstract description 26
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 claims abstract description 26
- 102100035221 Tyrosine-protein kinase Fyn Human genes 0.000 claims abstract description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 25
- 102100021604 Ephrin type-A receptor 6 Human genes 0.000 claims abstract description 24
- 101000898696 Homo sapiens Ephrin type-A receptor 6 Proteins 0.000 claims abstract description 24
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims abstract description 22
- 102100030779 Ephrin type-B receptor 1 Human genes 0.000 claims abstract description 19
- 101001064150 Homo sapiens Ephrin type-B receptor 1 Proteins 0.000 claims abstract description 19
- 101000606502 Homo sapiens Protein-tyrosine kinase 6 Proteins 0.000 claims abstract description 19
- 102100039810 Protein-tyrosine kinase 6 Human genes 0.000 claims abstract description 19
- PGYPOBZJRVSMDS-UHFFFAOYSA-N loperamide hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 PGYPOBZJRVSMDS-UHFFFAOYSA-N 0.000 claims abstract description 18
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 claims abstract description 17
- 102100036721 Insulin receptor Human genes 0.000 claims abstract description 17
- 101000889732 Homo sapiens Tyrosine-protein kinase Tec Proteins 0.000 claims abstract description 14
- 201000010099 disease Diseases 0.000 claims abstract description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 12
- 101001050476 Homo sapiens Tyrosine-protein kinase ITK/TSK Proteins 0.000 claims abstract description 9
- 102100023345 Tyrosine-protein kinase ITK/TSK Human genes 0.000 claims abstract description 9
- 238000003745 diagnosis Methods 0.000 claims abstract description 5
- 101001106413 Homo sapiens Macrophage-stimulating protein receptor Proteins 0.000 claims abstract 80
- 102100021435 Macrophage-stimulating protein receptor Human genes 0.000 claims abstract 80
- 102100031984 Ephrin type-B receptor 6 Human genes 0.000 claims abstract 74
- 101001064451 Homo sapiens Ephrin type-B receptor 6 Proteins 0.000 claims abstract 74
- 102100037813 Focal adhesion kinase 1 Human genes 0.000 claims abstract 61
- 101000878536 Homo sapiens Focal adhesion kinase 1 Proteins 0.000 claims abstract 61
- 102100038183 Tyrosine-protein kinase SYK Human genes 0.000 claims abstract 56
- 101000727826 Homo sapiens Tyrosine-protein kinase RYK Proteins 0.000 claims abstract 52
- 102100029759 Tyrosine-protein kinase RYK Human genes 0.000 claims abstract 52
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims abstract 50
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims abstract 50
- 101000663003 Homo sapiens Non-receptor tyrosine-protein kinase TNK1 Proteins 0.000 claims abstract 41
- 102100037669 Non-receptor tyrosine-protein kinase TNK1 Human genes 0.000 claims abstract 41
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 claims abstract 39
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 claims abstract 39
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims abstract 36
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims abstract 35
- 102100024537 Tyrosine-protein kinase Fer Human genes 0.000 claims abstract 33
- 108010067366 proto-oncogene protein c-fes-fps Proteins 0.000 claims abstract 33
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 claims abstract 31
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 claims abstract 31
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 claims abstract 29
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 claims abstract 29
- 101000606067 Homo sapiens Tyrosine-protein kinase TXK Proteins 0.000 claims abstract 25
- 102100039079 Tyrosine-protein kinase TXK Human genes 0.000 claims abstract 25
- 102100022007 Tyrosine-protein kinase receptor Tie-1 Human genes 0.000 claims abstract 24
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 claims abstract 21
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 claims abstract 21
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims abstract 21
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 claims abstract 20
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 claims abstract 20
- 101001059535 Homo sapiens Megakaryocyte-associated tyrosine-protein kinase Proteins 0.000 claims abstract 17
- 102100028905 Megakaryocyte-associated tyrosine-protein kinase Human genes 0.000 claims abstract 17
- 108010055211 EphA1 Receptor Proteins 0.000 claims abstract 16
- 102100030322 Ephrin type-A receptor 1 Human genes 0.000 claims abstract 16
- 102100021600 Ephrin type-A receptor 10 Human genes 0.000 claims abstract 13
- 101000898673 Homo sapiens Ephrin type-A receptor 10 Proteins 0.000 claims abstract 13
- 102100021606 Ephrin type-A receptor 7 Human genes 0.000 claims abstract 9
- 101000898708 Homo sapiens Ephrin type-A receptor 7 Proteins 0.000 claims abstract 9
- 101000820294 Homo sapiens Tyrosine-protein kinase Yes Proteins 0.000 claims abstract 9
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 claims abstract 9
- 102100021788 Tyrosine-protein kinase Yes Human genes 0.000 claims abstract 9
- 101000604583 Homo sapiens Tyrosine-protein kinase SYK Proteins 0.000 claims abstract 8
- 101000753253 Homo sapiens Tyrosine-protein kinase receptor Tie-1 Proteins 0.000 claims abstract 8
- 210000004027 cell Anatomy 0.000 claims description 60
- 150000007523 nucleic acids Chemical class 0.000 claims description 50
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 44
- 102000039446 nucleic acids Human genes 0.000 claims description 44
- 108020004707 nucleic acids Proteins 0.000 claims description 44
- 235000001014 amino acid Nutrition 0.000 claims description 33
- 229940024606 amino acid Drugs 0.000 claims description 33
- 230000035772 mutation Effects 0.000 claims description 31
- 108010069682 CSK Tyrosine-Protein Kinase Proteins 0.000 claims description 29
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 230000001965 increasing effect Effects 0.000 claims description 18
- 101150098329 Tyro3 gene Proteins 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 14
- 241000282414 Homo sapiens Species 0.000 claims description 10
- 102220198375 rs1057520036 Human genes 0.000 claims description 10
- 102200118192 rs33940204 Human genes 0.000 claims description 10
- 102220583129 Cellular tumor antigen p53_S46F_mutation Human genes 0.000 claims description 9
- 230000006907 apoptotic process Effects 0.000 claims description 9
- 102200108120 c.116C>T Human genes 0.000 claims description 9
- 102220364103 c.2033C>T Human genes 0.000 claims description 9
- 102220414533 c.292A>C Human genes 0.000 claims description 9
- 102220364111 c.3352G>A Human genes 0.000 claims description 9
- 102220364094 c.345T>A Human genes 0.000 claims description 9
- 102220318413 rs1263419082 Human genes 0.000 claims description 9
- 102220129090 rs139176878 Human genes 0.000 claims description 9
- 102220198019 rs149840192 Human genes 0.000 claims description 9
- 102200108158 rs201717599 Human genes 0.000 claims description 9
- 102220050990 rs28928900 Human genes 0.000 claims description 9
- 102200112655 rs34021505 Human genes 0.000 claims description 9
- 102200112686 rs34192549 Human genes 0.000 claims description 9
- 102220104604 rs372178531 Human genes 0.000 claims description 9
- 102200075749 rs397514044 Human genes 0.000 claims description 9
- 102220129084 rs757859957 Human genes 0.000 claims description 9
- 102220508661 Ephrin type-A receptor 5_N81T_mutation Human genes 0.000 claims description 8
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 8
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 230000014509 gene expression Effects 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 8
- 102220129862 rs144342633 Human genes 0.000 claims description 8
- 108020004414 DNA Proteins 0.000 claims description 7
- 210000004602 germ cell Anatomy 0.000 claims description 7
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 6
- 230000027455 binding Effects 0.000 claims description 6
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 238000005259 measurement Methods 0.000 claims description 6
- 102220197915 rs121913231 Human genes 0.000 claims description 6
- 239000004475 Arginine Substances 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- LHHKJQFIKHAUIA-MPPDQPJWSA-N amoxicilloic acid Chemical compound N1[C@@H](C(O)=O)C(C)(C)S[C@@H]1[C@@H](C(O)=O)NC(=O)[C@H](N)C1=CC=C(O)C=C1 LHHKJQFIKHAUIA-MPPDQPJWSA-N 0.000 claims description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 5
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 102220093308 rs63751199 Human genes 0.000 claims description 5
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
- 230000019491 signal transduction Effects 0.000 claims description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
- 108010021466 Mutant Proteins Proteins 0.000 claims description 3
- 102000008300 Mutant Proteins Human genes 0.000 claims description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 3
- 230000001594 aberrant effect Effects 0.000 claims description 3
- 230000005856 abnormality Effects 0.000 claims description 3
- 125000000539 amino acid group Chemical group 0.000 claims description 3
- 235000009582 asparagine Nutrition 0.000 claims description 3
- 229960001230 asparagine Drugs 0.000 claims description 3
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims description 3
- 230000006870 function Effects 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 239000004474 valine Substances 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- 101000606129 Homo sapiens Tyrosine-protein kinase receptor TYRO3 Proteins 0.000 claims 56
- 102100039127 Tyrosine-protein kinase receptor TYRO3 Human genes 0.000 claims 56
- 239000012634 fragment Substances 0.000 claims 38
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 claims 21
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 claims 21
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 18
- 239000002853 nucleic acid probe Substances 0.000 claims 18
- 239000000523 sample Substances 0.000 claims 13
- 101000807561 Homo sapiens Tyrosine-protein kinase receptor UFO Proteins 0.000 claims 11
- 102000042838 JAK family Human genes 0.000 claims 11
- 108091082332 JAK family Proteins 0.000 claims 11
- 230000004075 alteration Effects 0.000 claims 11
- 208000035475 disorder Diseases 0.000 claims 11
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims 8
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims 8
- 102220512846 Keratin, type I cytoskeletal 40_F85S_mutation Human genes 0.000 claims 8
- 102220639015 Methylglutaconyl-CoA hydratase, mitochondrial_K113Q_mutation Human genes 0.000 claims 8
- 102000018967 Platelet-Derived Growth Factor beta Receptor Human genes 0.000 claims 8
- 102220467227 Receptor tyrosine-protein kinase erbB-2_A1216D_mutation Human genes 0.000 claims 8
- 102220599985 Tyrosine-protein kinase JAK2_R1063H_mutation Human genes 0.000 claims 8
- 102220352275 c.1343G>A Human genes 0.000 claims 8
- 102220304248 rs1243381790 Human genes 0.000 claims 8
- 102220011774 rs139913632 Human genes 0.000 claims 8
- 102220316445 rs145955907 Human genes 0.000 claims 8
- 102200039339 rs146030737 Human genes 0.000 claims 8
- 102220046362 rs150478207 Human genes 0.000 claims 8
- 102220138137 rs150950017 Human genes 0.000 claims 8
- 102220086361 rs151286353 Human genes 0.000 claims 8
- 102200110980 rs28931570 Human genes 0.000 claims 8
- 102200039340 rs34172843 Human genes 0.000 claims 8
- 102200157260 rs34536443 Human genes 0.000 claims 8
- 102200157261 rs35018800 Human genes 0.000 claims 8
- 102200134838 rs35030851 Human genes 0.000 claims 8
- 102200112654 rs35903225 Human genes 0.000 claims 8
- 102200018234 rs36035373 Human genes 0.000 claims 8
- 102220224178 rs376197467 Human genes 0.000 claims 8
- 102220261192 rs74943037 Human genes 0.000 claims 8
- 102220224416 rs750825686 Human genes 0.000 claims 8
- 102220209659 rs752415137 Human genes 0.000 claims 8
- 102220260290 rs772974254 Human genes 0.000 claims 8
- 239000000126 substance Substances 0.000 claims 8
- 102220610463 Argininosuccinate synthase_A299D_mutation Human genes 0.000 claims 7
- 101000864342 Homo sapiens Tyrosine-protein kinase BTK Proteins 0.000 claims 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 7
- 102100022673 Nuclear receptor subfamily 4 group A member 3 Human genes 0.000 claims 7
- 230000002062 proliferating effect Effects 0.000 claims 7
- 102200018177 rs35597368 Human genes 0.000 claims 7
- 102220208635 rs55762744 Human genes 0.000 claims 7
- 102220242576 rs755307129 Human genes 0.000 claims 7
- 230000000295 complement effect Effects 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 102200034118 rs35764413 Human genes 0.000 claims 6
- 239000007787 solid Substances 0.000 claims 5
- 102220591921 Macrophage-stimulating protein receptor_R1335G_mutation Human genes 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- 102220597255 Proto-oncogene tyrosine-protein kinase ROS_D2213N_mutation Human genes 0.000 claims 4
- 102220597257 Proto-oncogene tyrosine-protein kinase ROS_K2228Q_mutation Human genes 0.000 claims 4
- 102220597293 Proto-oncogene tyrosine-protein kinase ROS_S1109L_mutation Human genes 0.000 claims 4
- 102220467229 Receptor tyrosine-protein kinase erbB-2_P1170A_mutation Human genes 0.000 claims 4
- 102220519199 Serine/threonine-protein kinase LMTK2_P30A_mutation Human genes 0.000 claims 4
- 102220458897 c.212T>C Human genes 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 102200057873 rs10079250 Human genes 0.000 claims 4
- 102220214605 rs1060502916 Human genes 0.000 claims 4
- 102200034102 rs10820900 Human genes 0.000 claims 4
- 102200062721 rs121917766 Human genes 0.000 claims 4
- 102200111635 rs13433937 Human genes 0.000 claims 4
- 102200006288 rs17158558 Human genes 0.000 claims 4
- 102200006127 rs1799939 Human genes 0.000 claims 4
- 102200003068 rs1881420 Human genes 0.000 claims 4
- 102200003069 rs1881421 Human genes 0.000 claims 4
- 102200108007 rs199473557 Human genes 0.000 claims 4
- 102200048803 rs2227983 Human genes 0.000 claims 4
- 102220039746 rs2229067 Human genes 0.000 claims 4
- 102220039743 rs2229071 Human genes 0.000 claims 4
- 102200018141 rs2229558 Human genes 0.000 claims 4
- 102200157279 rs2304256 Human genes 0.000 claims 4
- 102200087826 rs3212723 Human genes 0.000 claims 4
- 102200068470 rs33917957 Human genes 0.000 claims 4
- 102200143304 rs351855 Human genes 0.000 claims 4
- 102200087828 rs55778349 Human genes 0.000 claims 4
- 102200115706 rs6336 Human genes 0.000 claims 4
- 102220103991 rs764149793 Human genes 0.000 claims 4
- 102220098726 rs878853315 Human genes 0.000 claims 4
- 102220171126 rs886048378 Human genes 0.000 claims 4
- 102200004613 rs9282834 Human genes 0.000 claims 4
- 238000012360 testing method Methods 0.000 claims 4
- OIPMQULDKWSNGX-UHFFFAOYSA-N bis[[ethoxy(oxo)phosphaniumyl]oxy]alumanyloxy-ethoxy-oxophosphanium Chemical compound [Al+3].CCO[P+]([O-])=O.CCO[P+]([O-])=O.CCO[P+]([O-])=O OIPMQULDKWSNGX-UHFFFAOYSA-N 0.000 claims 3
- 238000009396 hybridization Methods 0.000 claims 3
- 102200157278 rs2304255 Human genes 0.000 claims 3
- 102220011602 rs386833396 Human genes 0.000 claims 3
- 102200114514 rs535274413 Human genes 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 claims 2
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 210000005229 liver cell Anatomy 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 239000000737 potassium alginate Substances 0.000 claims 2
- 230000000717 retained effect Effects 0.000 claims 2
- 102200033964 rs10761129 Human genes 0.000 claims 2
- 102220004851 rs121913670 Human genes 0.000 claims 2
- 102220034419 rs587777181 Human genes 0.000 claims 2
- 230000009870 specific binding Effects 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 1
- 102220597259 Proto-oncogene tyrosine-protein kinase ROS_S2229C_mutation Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004958 brain cell Anatomy 0.000 claims 1
- 102220350437 c.1577T>C Human genes 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 210000005265 lung cell Anatomy 0.000 claims 1
- 238000009877 rendering Methods 0.000 claims 1
- 102200134842 rs1334811 Human genes 0.000 claims 1
- 102220080068 rs150114699 Human genes 0.000 claims 1
- 102200087954 rs3213409 Human genes 0.000 claims 1
- 102200039346 rs35958982 Human genes 0.000 claims 1
- 102220221090 rs587778141 Human genes 0.000 claims 1
- 102220277287 rs768925694 Human genes 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 230000034512 ubiquitination Effects 0.000 claims 1
- 238000010798 ubiquitination Methods 0.000 claims 1
- 101150025643 Epha5 gene Proteins 0.000 abstract 1
- 102100021605 Ephrin type-A receptor 5 Human genes 0.000 abstract 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 7
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 235000004400 serine Nutrition 0.000 description 5
- 108700020796 Oncogene Proteins 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 235000002374 tyrosine Nutrition 0.000 description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 3
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000004715 cellular signal transduction Effects 0.000 description 2
- 230000006650 fundamental cellular process Effects 0.000 description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
- 230000004077 genetic alteration Effects 0.000 description 2
- 231100000118 genetic alteration Toxicity 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- 229940084651 iressa Drugs 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000000865 phosphorylative effect Effects 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000008521 threonine Nutrition 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102100035683 Axin-2 Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010049466 Erythroblastosis Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101150054472 HER2 gene Proteins 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108010020361 Oncogene Protein gp140(v-fms) Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008995 epigenetic change Effects 0.000 description 1
- 108700020302 erbB-2 Genes Proteins 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000341 threoninyl group Chemical class [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86817306P | 2006-12-01 | 2006-12-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG177225A1 true SG177225A1 (en) | 2012-01-30 |
Family
ID=39468190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2011095569A SG177225A1 (en) | 2006-12-01 | 2007-12-03 | Cancer-related protein kinases |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110008347A1 (enExample) |
| EP (1) | EP2094850B1 (enExample) |
| JP (1) | JP2010511382A (enExample) |
| SG (1) | SG177225A1 (enExample) |
| WO (1) | WO2008066498A1 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120208824A1 (en) | 2006-01-20 | 2012-08-16 | Cell Signaling Technology, Inc. | ROS Kinase in Lung Cancer |
| NZ577759A (en) * | 2007-01-11 | 2012-07-27 | Genentech Inc | Genetic variations of tyrosine kinase 2 resulting in an activated catalytic domain are associated with colon and stomach cancer |
| LT2199390T (lt) | 2007-08-30 | 2017-03-10 | Daiichi Sankyo Company, Limited | Anti-epha2 antikūnas |
| US8540998B2 (en) | 2007-12-24 | 2013-09-24 | Oxford Biotherapeutics Ltd. | Methods for treating cancer using ephrin type-A receptor 10 antibodies conjugated to cytotoxic agents |
| EP2252373B1 (en) * | 2008-02-05 | 2012-06-13 | Urifer Ltd | Novel fer -like protein, pharmaceutical compositions containing it and method for its use |
| JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
| EP2165710A1 (en) * | 2008-09-19 | 2010-03-24 | Institut Curie | Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor |
| EP2169071A1 (en) * | 2008-09-29 | 2010-03-31 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Rodent cancer model for human FGFR4 Arg388 polymorphism |
| CA2739615C (en) | 2008-10-10 | 2017-12-05 | Amgen Inc. | Fgf21 mutants comprising polyethylene glycol and uses thereof |
| CA2741087A1 (en) * | 2008-10-21 | 2010-04-29 | Bayer Healthcare Llc | Identification of signature genes associated with hepatocellular carcinoma |
| NZ593207A (en) | 2008-11-12 | 2012-10-26 | Tengion Inc | Isolated renal cells and uses thereof |
| US9364477B2 (en) | 2009-02-12 | 2016-06-14 | Cell Signaling Technology, Inc. | Mutant ROS expression in human cancer |
| JP2012525847A (ja) | 2009-05-05 | 2012-10-25 | アムジエン・インコーポレーテツド | Ｆｇｆ２１変異体およびその使用 |
| DK3248610T5 (da) | 2009-05-05 | 2024-10-07 | Amgen Inc | Fgf21-mutanter og anvendelser deraf |
| EP2336171A1 (en) * | 2009-12-11 | 2011-06-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Novel targets for the treatment of proliferative diseases |
| EP2558497A2 (en) | 2010-04-15 | 2013-02-20 | Amgen Inc. | Human fgf receptor and beta-klotho binding proteins |
| EP2380909A1 (en) * | 2010-04-26 | 2011-10-26 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | PTK-7 protein involved in breast cancer |
| US10077442B2 (en) | 2010-05-12 | 2018-09-18 | Inregen | Bioactive renal cells |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| WO2012068073A2 (en) | 2010-11-15 | 2012-05-24 | University Of Florida Research Foundation, Inc. | Therapeutic and diagnostic applications targeting tnk-1 |
| AU2011336650B2 (en) | 2010-12-01 | 2016-12-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric rabbit/human ROR1 antibodies |
| RU2014126098A (ru) * | 2011-11-30 | 2016-01-27 | Дженентек, Инк. | МУТАЦИИ ErbB3 ПРИ РАКЕ |
| US10293035B2 (en) | 2014-03-28 | 2019-05-21 | University Of Washington Through Its Center For Commercialization | Breast and ovarian cancer vaccines |
| CN107406492B (zh) * | 2014-09-03 | 2021-12-24 | 井标记生物 | 用于预测对蛋白激酶抑制剂的敏感性的生物标记物及其用途 |
| CA2961437C (en) * | 2014-10-09 | 2019-01-15 | F. Hoffmann-La Roche Ag | Mutations in the epidermal growth factor receptor kinase domain |
| AU2016270321B2 (en) * | 2015-05-29 | 2020-09-10 | Ignyta, Inc. | Compositions and methods for treating patients with RTK mutant cells |
| MX382526B (es) | 2015-10-23 | 2025-03-13 | Array Biopharma Inc | Compuestos de 2-piridazin-3(2h)-ona 2-aril sustituidas y 2-heteroaril sustituidas como inhibidores de las tirosina quinasas fgfr |
| EA201891066A1 (ru) | 2015-10-30 | 2018-10-31 | ЭнБиИ-ТЕРАПЬЮТИКС АГ | Антитела к ror1 |
| AU2017210327A1 (en) | 2016-01-20 | 2018-08-09 | Nbe-Therapeutics Ag | ROR1 antibody compositions and related methods |
| US11123372B2 (en) | 2016-07-29 | 2021-09-21 | Prokidney | Bioactive renal cells for the treatment of chronic kidney disease |
| CN106480205A (zh) * | 2016-11-11 | 2017-03-08 | 北京吉因加科技有限公司 | 用于同时检测多种突变类型的序列组合和探针 |
| IL271759B2 (en) | 2017-07-19 | 2024-01-01 | Ignyta Inc | Pharmaceutical preparations that include anthraxtinib |
| KR20230008269A (ko) | 2017-08-07 | 2023-01-13 | 엔비이-테라퓨틱스 아게 | 생체 내 내성이 높은 항체 약물 결합체 |
| JP7311498B2 (ja) | 2017-10-17 | 2023-07-19 | イグナイタ インコーポレイテッド | 薬学的組成物および剤形 |
| JP7041265B2 (ja) * | 2017-11-29 | 2022-03-23 | ソウル大学校産学協力団 | 抗－ｒｏｓ１抗体およびその用途 |
| WO2019133752A1 (en) * | 2017-12-28 | 2019-07-04 | Development Center For Biotechnology | A method for predicting drug efficacy |
| WO2020131627A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| CN113474337A (zh) | 2018-12-19 | 2021-10-01 | 奥瑞生物药品公司 | 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物 |
| WO2020179844A1 (ja) * | 2019-03-04 | 2020-09-10 | 公益財団法人東京都医学総合研究所 | Ｔｒｋ断片をコードする核酸構築物、及びその利用 |
| CN110031626A (zh) * | 2019-04-02 | 2019-07-19 | 浙江理工大学 | 一种用于胃肠道间质肿瘤迁移的标志物ack1及其应用 |
| US20230115945A1 (en) | 2019-12-30 | 2023-04-13 | Tyra Biosciences, Inc. | Aminopyrimidine compounds |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| WO2022147246A1 (en) | 2020-12-30 | 2022-07-07 | Tyra Biosciences, Inc. | Indazole compounds as kinase inhibitors |
| WO2022182972A1 (en) | 2021-02-26 | 2022-09-01 | Tyra Biosciences, Inc. | Aminopyrimidine compounds and methods of their use |
| WO2024006883A1 (en) | 2022-06-29 | 2024-01-04 | Tyra Biosciences, Inc. | Polymorphic compounds and uses thereof |
| AU2023300362A1 (en) | 2022-06-29 | 2025-01-09 | Tyra Biosciences, Inc. | Indazole compounds |
| WO2024138112A1 (en) | 2022-12-22 | 2024-06-27 | Tyra Biosciences, Inc. | Indazole compounds |
| TW202535368A (zh) | 2023-12-15 | 2025-09-16 | 美商泰拉生物科學公司 | 吲唑化合物 |
| WO2025222097A1 (en) | 2024-04-19 | 2025-10-23 | Tyra Biosciences, Inc. | Indazole-based protac degraders and their anticancer activity |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4343940A (en) * | 1979-02-13 | 1982-08-10 | Mead Johnson & Company | Anti-tumor quinazoline compounds |
| EP0031237B1 (en) * | 1979-12-19 | 1984-10-17 | National Research Development Corporation | Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents |
| US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| DE3611194A1 (de) * | 1986-04-04 | 1987-10-08 | Bayer Ag | Cancerostatisches mittel |
| US5217999A (en) * | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
| DE3920029C2 (de) * | 1988-06-30 | 1999-05-20 | Clariant Finance Bvi Ltd | Farbstoffe zum Färben von Kunststoffen |
| US5302606A (en) * | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
| US5330992A (en) * | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
| US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| SE517975C2 (sv) | 2000-05-30 | 2002-08-13 | Power Ab C | Fackverkskonstruktion av balkar sammansatta till ett tredimensionellt ramverk samt användning av en sådan fackverkskonstruktion |
| CA2425643A1 (en) * | 2000-10-11 | 2002-04-18 | Avalon Pharmaceuticals | Cancer-linked genes as targets for chemotherapy |
| US20050191618A1 (en) | 2001-05-18 | 2005-09-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA) |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US20060194265A1 (en) * | 2001-10-23 | 2006-08-31 | Morris David W | Novel therapeutic targets in cancer |
| AU2003225535A1 (en) * | 2002-01-31 | 2003-09-02 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating cancer |
| JP2006174701A (ja) * | 2003-02-24 | 2006-07-06 | Research Association For Biotechnology | 新規タンパク質およびそれをコードするｄｎａ |
| JP2005198640A (ja) * | 2003-11-25 | 2005-07-28 | Biomarker Science:Kk | 遺伝子発現方法 |
-
2007
- 2007-12-03 WO PCT/SG2007/000412 patent/WO2008066498A1/en not_active Ceased
- 2007-12-03 US US12/517,050 patent/US20110008347A1/en not_active Abandoned
- 2007-12-03 JP JP2009539218A patent/JP2010511382A/ja active Pending
- 2007-12-03 SG SG2011095569A patent/SG177225A1/en unknown
- 2007-12-03 EP EP07852282.8A patent/EP2094850B1/en not_active Not-in-force
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008066498A1 (en) | 2008-06-05 |
| EP2094850B1 (en) | 2013-06-12 |
| EP2094850A1 (en) | 2009-09-02 |
| JP2010511382A (ja) | 2010-04-15 |
| EP2094850A4 (en) | 2010-08-04 |
| US20110008347A1 (en) | 2011-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20110008347A1 (en) | Cancer-related protein kinases | |
| US9364477B2 (en) | Mutant ROS expression in human cancer | |
| US20100111944A1 (en) | Method of diagnosing, classifying and treating endometrial cancer and precancer | |
| US20100081153A1 (en) | Cancer associated protein kinases and their uses | |
| JP6387001B2 (ja) | Ｃｄｋ阻害剤と関連するバイオマーカー | |
| Goel et al. | The unique N‐terminal region of SRMS regulates enzymatic activity and phosphorylation of its novel substrate docking protein 1 | |
| Andrés-Pons et al. | In vivo functional analysis of the counterbalance of hyperactive phosphatidylinositol 3-kinase p110 catalytic oncoproteins by the tumor suppressor PTEN | |
| CN100578227C (zh) | 用于诊断和作为癌症治疗靶标的ttk | |
| US9464313B2 (en) | Biosensor for detecting RAF/KSR family kinase dimerization and uses thereof | |
| US20190094229A1 (en) | Methods of diagnosing, classifying and treating endometrial cancer and precancer | |
| Hosoya et al. | Identification of a SRC‐like tyrosine kinase gene, FRK, fused with ETV6 in a patient with acute myelogenous leukemia carrying at (6; 12)(q21; p13) translocation | |
| WO2012075318A2 (en) | Fn1 and alk gene translocations in cancer and alk kinase expression in ovarian cancer | |
| Montecchini | TERAPIA DI PRECISIONE PER LA LEUCEMIA LINFOBLASTICA ACUTA PEDIATRICA BCR-ABL-LIKE: SVILUPPO DI UN SISTEMA IN VITRO PER LA DIAGNOSI E IL MONITORAGGIO CLINICO | |
| Shillingford | Insights into the Allosteric Regulation and Exploitation of the MAPK Phosphatases as Therapeutic Targets | |
| Montecchini et al. | A novel peptide biosensor for screening ABL1 activity in vitro: a challenge for precision therapy in BCR-ABL1 and BCR-ABL1 like leukemias. | |
| CN117795340A (zh) | 生物标志物及其用途 | |
| Mutic | Effect of MAPK inhibition on cell cycle regulation of thymidine kinase 1 and [18F]-FLT PET | |
| AU2007237228A1 (en) | Cancer associated protein kinases and their uses | |
| HK1210482B (en) | Mutant ros expression in human liver cancer | |
| JP2005245403A (ja) | アポトーシス調節活性を測定する方法、及びアポトーシス調節活性を有する化合物のスクリーニング方法 | |
| HK1165007B (en) | Mutant ros expression in human liver cancer |